BRAF and melanoma: Nelfinavir sensitized BRAF-mutated melanoma cells to MEK inhibitors and BRAF inhibitors via SMAD-mediated downregulation of PAX and MITF, and decreased phosphorylation of ERK during combination with inhibitors of MEK or BRAF [113].